Associated Papers
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.
Wu SG et al.
Erj Open Research, 2017
Rational design of non-resistant targeted cancer therapies.
Martínez-Jiménez F et al.
Scientific Reports, 2017
Select a paper to view details